Should the patent system for new medicines be abolished?

dc.contributor.author

DiMasi, JA

dc.contributor.author

Grabowski, HG

dc.coverage.spatial

United States

dc.date.accessioned

2013-04-23T16:54:45Z

dc.date.issued

2007-11

dc.identifier

https://www.ncbi.nlm.nih.gov/pubmed/17952100

dc.identifier

6100393

dc.identifier.eissn

1532-6535

dc.identifier.uri

https://hdl.handle.net/10161/6721

dc.language

eng

dc.publisher

Springer Science and Business Media LLC

dc.relation.ispartof

Clin Pharmacol Ther

dc.relation.isversionof

10.1038/sj.clpt.6100393

dc.subject

Biomedical Research

dc.subject

Commerce

dc.subject

Cost-Benefit Analysis

dc.subject

Drug Costs

dc.subject

Drug Industry

dc.subject

Financing, Government

dc.subject

Humans

dc.subject

Insurance Coverage

dc.subject

Legislation, Drug

dc.subject

Orphan Drug Production

dc.subject

Patents as Topic

dc.subject

Pharmaceutical Preparations

dc.subject

Public Policy

dc.subject

United States

dc.title

Should the patent system for new medicines be abolished?

dc.type

Journal article

pubs.author-url

https://www.ncbi.nlm.nih.gov/pubmed/17952100

pubs.begin-page

488

pubs.end-page

490

pubs.issue

5

pubs.organisational-group

Duke

pubs.organisational-group

Economics

pubs.organisational-group

Trinity College of Arts & Sciences

pubs.publication-status

Published

pubs.volume

82

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Macroscopy.pdf
Size:
96.61 KB
Format:
Adobe Portable Document Format